News

Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar ...
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...
The Manila Times3d
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar ...
The Manila Times2d
Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar ...
Taiwan News4d
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds ...
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million ...
Alvotech, Dr Reddy’s ink pack to co-develop Biosimilar for cancer treatment
Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.
Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...
Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda
Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...
Morningstar4d
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...
Morningstar4d
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories ...